Infectious Disease · Medical Literature
Individual-level HPV vaccination verification in Botswana: lessons learned from implementation of the HOPE II trial.
Abstract
The World Health Organization (WHO) estimated 660,000 new cervical cancer cases and 350,000 deaths globally in 2022, with over 90% occurring in low- and middle-income countries (LMICs). Global elimination targets call for vaccination of >90% of girls against human papillomavirus (HPV) by age 15 by 2030. While Botswana's national policy aligns with these targets, progress monitoring is constrained by fragmented, predominantly paper-based health information systems. We describe our experience verifying individual-level HPV vaccination status among adolescent girls and young women living with HIV (AGYWLWH) in Botswana. This activity was conducted to determine eligibility for the HOPE II trial, a randomized controlled study evaluating the efficacy of a single-dose nonavalent HPV vaccine. Verification followed the national rollout of school-based HPV vaccination in 2015, targeting girls aged 9-13 years. Participants provided pre-screening consent for review of vaccination records held in school health systems, Ministry of Health (MoH) registers, and participant-held vaccination cards where available. We sought HPV vaccination records for 80 potential participants across 80 schools and 68 clinics. Only 15 participants (18.8%) had verifiable records: 2 (2.5%) retained vaccination cards, 4 (5.0%) had documentation in school records, and 9 (11.3%) had entries in MoH registers. Most school records were incomplete or missing, and several sites reported loss or disposal of records due to relocation, fire damage, or storage constraints. These findings highlight critical gaps in HPV vaccination documentation. Strengthening electronic immunization registries, standardizing record transfer, and improving data integration could enhance monitoring and support equitable progress toward cervical cancer elimination.
Clinical relevance
Among adolescent girls and young women living with HIV (AGYWLWH) in Botswana, how reliably can individual-level HPV vaccination status be verified through existing school health systems, Ministry of Health registers, and participant-held vaccination cards when determining trial eligibility? __SNAPSHOT__ {"studyDesign":"Implementation science / descriptive report embedded within the pre-screening phase of a randomized controlled trial (HOPE II)","setting":"Botswana; multi-site school and community health settings spanning 80 schools and 68 clinics across the country","sampleSize":"n=80 potential trial participants sought across 80 schools and 68 clinics","population":"Adolescent girls and young women living with HIV (AGYWLWH) eligible for pre-screening for the HOPE II RCT; target age group consistent with Botswana's 2015 national school-based HPV vaccination rollout (girls aged 9–13 years at time of original vaccination)","intervention":"Multi-source individual-level HPV vaccination record verification (participant-held vaccination cards, school health system records, and Ministry of Health registers)","comparator":"Not applicable (single-arm descriptive activity)","primaryOutcome":"Proportion of potential participants with verifiable individual-level HPV vaccination records, stratified by documentation source (vaccination card, school records, MoH registers)","followUp":"Cross-sectional (single verification effort at time of HOPE II pre-screening; exact dates not reported in abstract)","fundingSource":"Not reported in abstract"}
Key findings
Of 80 potential HOPE II trial participants for whom HPV vaccination record verification was attempted across 80 schools and 68 clinics, only 15 individuals (18.8%) had verifiable documentation of vaccination status. Among those with confirmed records, 2 participants (2.5%) retained personal vaccination cards, 4 (5.0%) had documentation in school records, and 9 (11.3%) had entries in Ministry of Health registers. Collectively, these three sources were non-overlapping in that the abstract presents them as additive to reach the 18.8% figure. The remaining 81.2% of participants (65 of 80) (calculated) had no verifiable record from any source. Specific causes of record unavailability included incomplete or missing school records, as well as loss or disposal of records due to institutional relocation, fire damage, and storage constraints. No efficacy, clinical outcome, or adverse event data are reported, as this was a verification sub-activity rather than a clinical intervention.
Practice implications
This descriptive report establishes that paper-based, fragmented vaccination record systems in Botswana are severely inadequate for individual-level HPV vaccination verification, with records recoverable for fewer than 1 in 5 potential trial participants. These findings directly impair the conduct of the HOPE II RCT, which requires confirmation of prior single-dose HPV vaccination as an eligibility criterion. The results do not establish the actual proportion of AGYWLWH who were vaccinated versus unvaccinated — only that records could not be located, meaning that true vaccination coverage among this cohort remains unknown from this study. Generalizability is limited to post-rollout LMIC settings with analogous paper-based systems. Clinicians and public health practitioners should not interpret these findings as evidence of low vaccination coverage per se, but rather as evidence that documentation infrastructure is insufficient to support either clinical trial eligibility determination or national surveillance. Because only an abstract was available, full methodological details, site-level variation, and participant demographic characteristics could not be assessed. Results are not intended as individualized clinical guidance. __LIMITATIONS__ 1. Descriptive/observational design with no comparator and no formal hypothesis testing; no statistical inference is warranted. 2. Small convenience sample (n=80) from a single country, limiting generalizability to other LMICs even those with similar infrastructure challenges. 3. Inability to distinguish true non-vaccination from documentation failure — the 81.2% without verifiable records may include vaccinated individuals whose records were lost, introducing ascertainment bias. 4. Retrospective record retrieval approximately 8–13 years after the 2015 school-based rollout, with time-related record loss (fire, relocation, disposal) as acknowledged confounders. 5. No electronic or cross-reference validation methodology described in the abstract; record-matching fidelity not reported. 6. Participant self-report of vaccination status not described as a supplementary verification method. 7. Funding source not reported, precluding assessment of potential sponsor influence. 8. Full article not reviewed — conclusions are based solely on the published abstract. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In Botswana's fragmented, paper-based immunization documentation environment, individual-level HPV vaccination status could only be verified for 18.8% of AGYWLWH screened for the HOPE II trial, with MoH registers being the most productive single source (11.3%). These findings underscore an urgent public health systems gap: without robust electronic immunization registries, neither clinical trial eligibility adjudication nor national cervical cancer elimination progress monitoring can be reliably performed. Investment in digital immunization information systems and standardized record-transfer protocols is essential to achieving WHO's 90% HPV vaccination coverage target in LMICs.